TScan Therapeutics (TCRX) Stock Forecast & Price Target

TScan Therapeutics is supported by encouraging Cohort C data showing complete donor chimerism in all 13 patients as of August 27th, including two previously relapsed patients who responded after a third dose of TSC-101 and/or maintenance therapy. The 6-month relapse rate of about 20% in 14 patients with 86% MRD+ remains favorable versus historic relapse rates of roughly 45% in MRD+ and 20% in MRD- patients post HSCT, reinforcing the clinical rationale for its TCR-T platform. Financially, the ~75% RIF is expected to drive about $55M in cumulative savings through YE:27, while 2Q:26 cash of $100M and runway into 4Q:27 provide meaningful but not unlimited funding ahead of required debt repayments beginning in 4Q:26.

TScan Therapeutics is facing a materially weaker fundamental profile after pausing ALLOHA-2, which removes its most advanced asset, TSC-101, from core valuation and leaves future heme development dependent on a strategic partner. The company’s pivot to two preclinical in vivo TCR-T programs targeting PRAME and MAGE-A4 pushes meaningful clinical readouts out to 1Q27, with an IND filing in 3Q27 and first Phase 1 development not expected until 4Q27, increasing execution and regulatory risk. Although management expects ~$55M of cumulative savings and runway into 4Q27 after a 75% workforce reduction and manufacturing shutdown, that cash extension appears only sufficient to reach initial clinical entry, leaving a persistent financing overhang.